Drug news
Janacti (Merck Inc.) withdrawn in Europe for Type 2 Diabetes
Merck has withdrawn its application for centralised marketing authorisation in Europe for Janacti(sitagliptin and pioglitazone), for the 100/30 mg and 100/45 mg fixed-dose combination tablets, based on a review of the regulatory and commercial prospects for the fixed-dose combination product.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.